GE HealthCare TechnologiesSTU:L0T +1.37%72 EBITDA Margin % is 14.71% as of Mar. 2026, which is 20% below its 10-year median of 18.36. GuruFocus rates STU:L0T with a GF Score™ of 72/100 and a GF Value™ of €74.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, GE HealthCare Technologies ranks better than 70.47% on this metric.
GE HealthCare Technologies (STU:L0T) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GE HealthCare Technologies EBITDA Margin % Related Terms
GE HealthCare Technologies EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L0T vs DXCM, STE, ZBH: EBITDA Margin % Comparison
For the Medical Devices subindustry, GE HealthCare Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GE HealthCare Technologies EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GE HealthCare Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GE HealthCare Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GE HealthCare Technologies (STU:L0T) has a EBITDA Margin % of 14.71% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GE HealthCare Technologies and its competitors. This is 20% below median its historical median of 18.36. Over the past decade, GE HealthCare Technologies' EBITDA Margin % has ranged from 17.06 to 20.13. According to the industry distribution chart, GE HealthCare Technologies ranks #241 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 29.5%.
Is GE HealthCare Technologies' EBITDA Margin % too high?
GE HealthCare Technologies' current EBITDA Margin % of 14.71% is 20% below median its 10-year median of 18.36. Over the past 10 years, this metric has ranged from a low of 17.06 to a high of 20.13. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. GE HealthCare Technologies' value of 14.71% is 96.8% above this industry median. Based on the distribution chart, GE HealthCare Technologies ranks #241 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, GE HealthCare Technologies has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GE HealthCare Technologies' EBITDA Margin % compare to DXCM and STE?
According to the Medical Devices & Instruments industry distribution chart, GE HealthCare Technologies ranks #241 out of 816 companies for EBITDA Margin %. This puts GE HealthCare Technologies in the upper half of its industry. The industry median EBITDA Margin % is 7.48. GE HealthCare Technologies' value of 14.71% is 96.8% above this benchmark. Historically, GE HealthCare Technologies' own EBITDA Margin % has ranged from 17.06 to 20.13 over the past decade. While the company's 10-year median is 18.36 vs. the industry median of 7.48, GE HealthCare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GE HealthCare Technologies's current EBITDA Margin % of 14.71% is 96.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GE HealthCare Technologies and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GE HealthCare Technologies's current EBITDA Margin % is 14.71%, which is 20% below median its own 10-year median of 18.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GE HealthCare Technologies stock overvalued right now?
Based on GuruFocus' analysis, GE HealthCare Technologies (STU:L0T) is currently considered Modestly Undervalued. The stock's GF Value™ is €74.58, compared to a current price of €57.67 — trading 22.7% below its estimated fair value. The current EBITDA Margin % is 14.71%, which is 20% below median its 10-year median of 18.36 and 96.8% above the Medical Devices & Instruments industry median of 7.48. GE HealthCare Technologies' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GE HealthCare Technologies (STU:L0T), the current EBITDA Margin % is 14.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GE HealthCare Technologies (STU:L0T) Overvalued in 2026?
Based on GuruFocus' analysis, GE HealthCare Technologies stock appears to be undervalued.
The current stock price of €57.67 is trading 22.7% below its estimated GF Value™ of €74.58.
GuruFocus considers GE HealthCare Technologies to be Modestly Undervalued.
Key valuation signals for STU:L0T:
EBITDA Margin %: 14.71% (20% below median its 10-year median of 18.36)
GF Value™: €74.58 vs. price of €57.67 (22.7% below fair value)
Industry Position: 96.8% above the Medical Devices & Instruments median (#241 of 816)
No single metric tells the full story. See the STU:L0T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
72GF Score
Get the complete analysis for STU:L0T
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L0T has been successfully added to your 
